During the last 10-15 years, cytochrome P450 (CYP) 2C8 has emerged as an important drug-
metabolizing enzyme. CYP2C8 is highly expressed in human liver and is known to …

Cytochrome P450, family 2, subfamily C, polypeptide 8 (CYP2C8) is a phase I metabolizing
enzyme that plays an integral role in the biotransformation of structurally diverse xenobiotics …

Purpose CYP2B6 liver enzyme metabolizes the two non-nucleoside reverse transcriptase
inhibitors Efavirenz (EFV) and Nevirapine (NVP) used in the antiretroviral therapy (ART) …

Introduction Artemisinin-based combination therapies (ACTs) are recommended first-line
antimalarials for uncomplicated Plasmodium falciparum malaria. Pharmacokinetic …

Background. Natural medicinal products are commonly used as a remedy against malaria
infections in African populations and have become a major source of information for the …

Malaria remains one of the deadliest diseases in Africa, particularly for children. While
successful in reducing morbidity and mortality, antimalarial treatments are also a major …

Human cytochrome P450 2C8 is a highly polymorphic gene and shows variation according
to ethnicity. The CYP2C8* 2 is a slow drug metabolism allele and shows 10–24% frequency …

Countries in Africa have a high burden of communicable disease, and are experiencing an
increase in noncommunicable diseases due to the effects of globalization, industrialization …

Abstract Background Cytochrome P450 (CYP) enzymes are essential in the metabolism of
most drugs used today. Single nucleotide polymorphism (s) occurring in CYP genes can …

Background In Eritrea, artesunate–amodiaquine is the first-line treatment against
uncomplicated malaria. Amodiaquine, which is mainly bio-transformed by CYP2C8, is …